- Home
- XBIO vs SILO Comparison
XBIO vs SILO Comparison
Compare XBIO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- SILO
- Stock Information
- Founded
- XBIO N/A
- SILO 2010
- Country
- XBIO United States
- SILO United States
- Employees
- XBIO N/A
- SILO N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- XBIO Health Care
- SILO Consumer Discretionary
- Exchange
- XBIO Nasdaq
- SILO Nasdaq
- Market Cap
- XBIO 4.2M
- SILO 4.5M
- IPO Year
- XBIO N/A
- SILO N/A
- Fundamental
- Price
- XBIO $4.08
- SILO $0.58
- Analyst Decision
- XBIO Hold
- SILO
- Analyst Count
- XBIO 1
- SILO 0
- Target Price
- XBIO N/A
- SILO N/A
- AVG Volume (30 Days)
- XBIO 187.0K
- SILO 311.1K
- Earning Date
- XBIO 08-12-2025
- SILO 08-12-2025
- Dividend Yield
- XBIO N/A
- SILO N/A
- EPS Growth
- XBIO N/A
- SILO N/A
- EPS
- XBIO N/A
- SILO N/A
- Revenue
- XBIO $2,582,728.00
- SILO $72,102.00
- Revenue This Year
- XBIO $14.23
- SILO $1.86
- Revenue Next Year
- XBIO $7.14
- SILO N/A
- P/E Ratio
- XBIO N/A
- SILO N/A
- Revenue Growth
- XBIO 5.63
- SILO N/A
- 52 Week Low
- XBIO $2.20
- SILO $0.41
- 52 Week High
- XBIO $5.27
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- XBIO 61.16
- SILO 44.04
- Support Level
- XBIO $3.44
- SILO $0.60
- Resistance Level
- XBIO $4.46
- SILO $0.64
- Average True Range (ATR)
- XBIO 0.63
- SILO 0.04
- MACD
- XBIO 0.05
- SILO 0.00
- Stochastic Oscillator
- XBIO 54.79
- SILO 2.48
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.